Data as of Nov 4, 2026.
BIOY vs XLII: Dividend Yield & Total Return
BIOY and XLII both write options for income.
askIQ about this page
askIQ about BIOY and XLII
Net assets on Nov 3, 2026: $1.5m for GraniteShares YieldBOOST Biotech ETF and $18m for State Street Industrial Select Sector SPDR Premium Income ETF.
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
26.1% as cash
13.6 pts behind XBI
Total return, distributions reinvested
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
13.6 pts behind XBI
26.1% of it arrived as cash. Total return, distributions reinvested. BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.0.9 pts behind XLI
XLII over 1 year: paid 13.3%, price −2.1%, total +11.4%, XLI +12.3%, −0.9 pts. Data to Nov 4, 2026.
XLI
+12.3%
XLII
+11.4%
13.3% of it arrived as cash
0.9 pts behind XLI
Total return, distributions reinvested
0.9 pts behind XLI
XLII over 1 year: paid 13.3%, price −2.1%, total +11.4%, XLI +12.3%, −0.9 pts. Data to Nov 4, 2026.
XLI
+12.3%
XLII
+11.4%
13.3% cash
0.9 pts behind XLI
13.3% of it arrived as cash. Both charts share one scale, with zero at the line. XLII over 1 year: paid 13.3%, price −2.1%, total +11.4%, XLI +12.3%, −0.9 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
XLII costs 0.83 points a year less; XLII is 12.0 times larger.
Points (pts) are percentage points.
| Measure | BIOY | XLII |
|---|---|---|
| Paid and earned | ||
| Total return, 1 year | not published | +11.4% |
| Price change | fell 21.9% (since May 5, 2026) | fell 2.1% (1 year) |
| Return of capital, issuer estimate | 96% of the Sep 22, 2026 payment | 100% of the Nov 5, 2026 payment |
| Against its benchmark | ||
| Benchmark | Biotech, measured through XBI | Industrials, measured through XLI |
| Cost and size | ||
| Expense ratio | 1.18% | 0.35% |
| Net assets, as of Nov 3, 2026 | $1.5m | $18m |
| Holdings | ||
| Holdings in common | 0% | |
What they share
By the books each fund has filed, BIOY and XLII hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 3, 2026.
half
0% in common
Only in one fund ↓
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | BIOY | XLII | BIOY | XLII | BIOY | XLII |
| 3 months | +6.9% | −6.2% | 14.5% | 2.7% | +2.9 pts | +2.6 pts |
| 6 months | +4.4% | +1.1% | 25.9% | 6.4% | −11.3 pts | +4.8 pts |
| 1 year | – | +11.4% | – | 13.3% | – | −0.9 pts |
| Since launchNot the same days: BIOY May 2026 · XLII Jul 2025 | +5.4% | +15.0% | 26.1% | 16.8% | −13.7 pts | +1.8 pts |
– means no data for this window. Open this comparison in the app →
BIOY
Over the period from its first trade on May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting value in cash distributions while its price fell 21.9%. With every distribution reinvested, the fund returned +5.4%. Biotech (XBI) returned +19.0% over the same days, so a holder was behind by 13.6 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 60.7%, paid weekly. GraniteShares estimates that 96% of the distribution paid Sep 22, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
XLII
Over the year to Nov 4, 2026, XLII paid 13.3% of its starting value in cash distributions while its price fell 2.1%. With every distribution reinvested, the fund returned +11.4%. Industrials (XLI) returned +12.3% over the same days, so a holder was behind by 0.9 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 15.0%, paid monthly. State Street estimates that 100% of the distribution paid Nov 5, 2026 was a return of capital (its 19a-1 notice).
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Overlap adds up the smaller of the two weights for each security both funds hold.
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, BIOY against XLII, data as of Nov 4, 2026. https://etfiq.com/compare/income/bioy-vs-xlii
ETFIQ. (Nov 4, 2026). BIOY against XLII. Retrieved from https://etfiq.com/compare/income/bioy-vs-xlii
[BIOY against XLII (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/bioy-vs-xlii)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.